Robert W Frenck

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. pmc Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Vaccine 29:5666-74. 2011
  2. doi request reprint The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, MLC 6014, Cincinnati, OH 45229, USA
    Expert Opin Biol Ther 12:63-77. 2012
  3. doi request reprint Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older
    Robert W Frenck
    Division of Infectious Diseases, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA Electronic address
    Vaccine 34:3454-62. 2016
  4. doi request reprint Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, United States Electronic address
    Vaccine 35:375-384. 2017
  5. pmc Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Clin Vaccine Immunol 19:1296-303. 2012
  6. doi request reprint Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine
    Robert Frenck
    Cincinnati Children s Hospital Medical Center, Department of Pediatrics, Cincinnati, OH 45229, USA
    Pediatr Infect Dis J 30:1086-91. 2011

Detail Information

Publications6

  1. pmc Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Vaccine 29:5666-74. 2011
    ..The reduced 3 μg dose administered ID by needle and syringe, as well as the 6 μg ID for subjects aged 50-64 years of age generated poorer immune responses as compared to the 15 μg IM dose...
  2. doi request reprint The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, MLC 6014, Cincinnati, OH 45229, USA
    Expert Opin Biol Ther 12:63-77. 2012
    ..Pneumococcal conjugate vaccines (PCVs) have been developed for use in infants and children aged less than 5 years, and are being studied for use in adult populations...
  3. doi request reprint Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older
    Robert W Frenck
    Division of Infectious Diseases, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA Electronic address
    Vaccine 34:3454-62. 2016
    ..A study to describe antibody persistence after vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) and response to revaccination 5 years after the initial dose was conducted...
  4. doi request reprint Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, United States Electronic address
    Vaccine 35:375-384. 2017
    ..A preliminary S. aureus three-antigen vaccine (SA3Ag) was reformulated to include a novel manganese transporter protein (MntC or rP305A). This study describes the first-in-human dose-finding, safety, and immunogenicity results for SA4Ag...
  5. pmc Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults
    Robert W Frenck
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Clin Vaccine Immunol 19:1296-303. 2012
    ..Given the positive immunologic attributes of PCV13, concomitant administration with TIV should be dictated by clinical circumstances...
  6. doi request reprint Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine
    Robert Frenck
    Cincinnati Children s Hospital Medical Center, Department of Pediatrics, Cincinnati, OH 45229, USA
    Pediatr Infect Dis J 30:1086-91. 2011
    ..This open-label study evaluated the immunogenicity and safety of administering PCV13 to healthy children previously vaccinated with PCV7...